CEACAM5 and neoplasm: To assess T cell activation in the periphery, a set of MC38-CEA tumor-bearing mice were treated as described in figure 2A and spleens were harvested from treated mice at day 28, stimulated in vitro with CD3 antibody, and evaluated for CD4+ and CD8+ T cell responses.